tizanidine (zanaflex) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Tizanidine is a short-acting drug for the management of spasticity. Tizanidine is an agonist at a2-adrenergic receptor sites and presumably reduces spasticity by increasing presynaptic inhibition of motor neurons. In animal models, tizanidine has no direct effect on skeletal muscle fibers or the neuromuscular junction, and no major effect on monosynaptic spinal reflexes. The effects of tizanidine are greatest on polysynaptic pathways. The overall effect of these actions is thought to reduce facilitation of spinal motor neurons. Side effects include dizziness, drowsiness, weakness, nervousness, hallucinations, depression, vomiting, dry mouth, constipation, diarrhea, stomach pain, heartburn, increased muscle spasms, back pain, rash, sweating, and a tingling sensation in the arms, legs, hands, and feet.   NCATS

Chemistry

More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$0.0347 - $5.2119
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

2,1,3-benzothiadiazol-4-amine, 5-chloro-n-(4,5-dihydro-1h-imidazol-2-yl)- | 5-chloro-4-(2-imidazolin-2-yl-amino)-2,1,3-benzothiadiazole | 5-chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiadiazole | acorda brand of tizanidine hydrochloride | an021 | an-021 | ds 103-282 | ds-103-282 | ds103-282 | novartis brand of tizanidine hydrochloride | sanofi synthelabo brand of tizanidine hydrochloride | sirdalud | sirdalud mr | sparc1401 | tizanidin | tizanidina | tizanidine | tizanidine hcl | tizanidine hydrochloride | tizanidine monohydrochloride | tizanidinum | zanaflex

Organizations (57)

Research & Development (33)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (26)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (23)

Approved Indications (1)


 

Muscle Spasticity

Experimental Indications - Clinical Trial Phases 1-4 (23)


 

Acute Pain (Phase 2)

Arthropathy, Neurogenic (Phase 4)

Back Pain (Phase 3)

Brain Injuries, Traumatic (Phase 1)

Chronic Pain (Phase 3)

Drug Interactions (Early Phase 1)

Healthy Volunteers (Phase 1)

Hernia, Inguinal (Phase 4)

Low Back Pain (Phase 4)

Melanoma (Phase 1)

Migraine with Aura (Phase 3)

Migraine without Aura (Phase 3)

Multiple Sclerosis (Phase 3)

Muscle Spasticity (Phase 4)

Neck Pain (Phase 3)

Opioid-Related Disorders (Phase 3)

Radiculopathy (Phase 3)

Shoulder Pain (Phase 4)

Sleep Disorders, Intrinsic (Phase 2)

Spinal Cord Injuries (Phase 3)

Stroke (Phase 3)

Substance-Related Disorders (Phase 1)

Thyroidectomy (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 25
  • # of Trial Organizations: 33

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue